AU2010343095B2 - Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof - Google Patents

Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof Download PDF

Info

Publication number
AU2010343095B2
AU2010343095B2 AU2010343095A AU2010343095A AU2010343095B2 AU 2010343095 B2 AU2010343095 B2 AU 2010343095B2 AU 2010343095 A AU2010343095 A AU 2010343095A AU 2010343095 A AU2010343095 A AU 2010343095A AU 2010343095 B2 AU2010343095 B2 AU 2010343095B2
Authority
AU
Australia
Prior art keywords
protein
schizochytrium
seq
membrane
microalgal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010343095A
Other languages
English (en)
Other versions
AU2010343095A1 (en
Inventor
Kirk Emil Apt
Anne-Cecile V. Bayne
James Casey Lippmeier
Ross Eric Zirkle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccine Technologies SAS
Original Assignee
Sanofi Vaccine Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Vaccine Technologies SAS filed Critical Sanofi Vaccine Technologies SAS
Publication of AU2010343095A1 publication Critical patent/AU2010343095A1/en
Assigned to SANOFI VACCINE TECHNOLOGIES, S.A.S. reassignment SANOFI VACCINE TECHNOLOGIES, S.A.S. Request for Assignment Assignors: DSM IP ASSETS B.V.
Application granted granted Critical
Publication of AU2010343095B2 publication Critical patent/AU2010343095B2/en
Priority to AU2017202195A priority Critical patent/AU2017202195B2/en
Priority to AU2019206054A priority patent/AU2019206054B2/en
Priority to AU2022203980A priority patent/AU2022203980B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010343095A 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof Active AU2010343095B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017202195A AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29046909P 2009-12-28 2009-12-28
US29044109P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12
PCT/US2010/062276 WO2011090731A1 (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202195A Division AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Publications (2)

Publication Number Publication Date
AU2010343095A1 AU2010343095A1 (en) 2012-08-09
AU2010343095B2 true AU2010343095B2 (en) 2017-01-05

Family

ID=44307127

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2010343095A Active AU2010343095B2 (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2017202195A Active AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A Active AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A Active AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017202195A Active AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A Active AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A Active AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Country Status (9)

Country Link
US (3) US20110189228A1 (forum.php)
EP (3) EP4130273B1 (forum.php)
JP (5) JP6339548B2 (forum.php)
CN (2) CN107746869A (forum.php)
AU (4) AU2010343095B2 (forum.php)
CA (3) CA3028175C (forum.php)
EA (1) EA022841B1 (forum.php)
IN (1) IN2012DN06277A (forum.php)
WO (1) WO2011090731A1 (forum.php)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350854B (en) 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
ES2752196T3 (es) * 2009-03-16 2020-04-03 Dsm Ip Assets Bv Producción de proteínas en microorganismos del filo Labyrinthulomycota
EA030095B1 (ru) * 2009-12-28 2018-06-29 ДиЭсЭм АйПи АССЕТС Б.В. Получение белка гемагглютинин-нейраминидазы в микроводорослях
CN103260643A (zh) * 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
CN107630017A (zh) 2011-03-07 2018-01-26 Dsm营养产品股份公司 工程化破囊壶菌属微生物
CN103748226A (zh) 2011-08-24 2014-04-23 诺维信股份有限公司 获得丝状真菌宿主细胞的阳性转化体的方法
US9090889B2 (en) 2012-07-24 2015-07-28 Bp Corporation North America Inc. Xylose isomerases and their uses
WO2014045191A2 (en) * 2012-09-18 2014-03-27 Myko Tech Private Limited Extracellular polysaccharides from labyrinthulomycetes with broad-spectrum antiviral activities
US11464244B2 (en) 2014-10-02 2022-10-11 Evonik Operations Gmbh Feedstuff of high abrasion resistance and good stability in water, containing PUFAs
CA2958463C (en) 2014-10-02 2022-05-03 Evonik Industries Ag Method for raising animals
BR112017006834B1 (pt) * 2014-10-02 2022-04-26 Evonik Operations Gmbh Processo para a preparação de um alimento para animais compreendendo pufas, produto extrudado de alimento para animais e método de criação de animais
ES2870093T3 (es) 2014-10-02 2021-10-26 Evonik Operations Gmbh Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
AU2016293487B2 (en) * 2015-07-13 2021-07-01 MARA Renewables Corporation Enhancing microalgal metabolism of xylose
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
JP2019529400A (ja) * 2016-09-09 2019-10-17 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 硝子体小胞中の核酸、タンパク質及び小分子の送達方法
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
US10954280B2 (en) 2016-11-27 2021-03-23 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from micro algae
CN111954713A (zh) * 2018-03-05 2020-11-17 科纳根公司 用于产生具有低硫酸化的糖分子的生物体和方法
AU2019293111A1 (en) 2018-06-27 2021-01-07 Sumitomo Electric Industries, Ltd. Original form body of flexible printed-wiring board, method of manufacturing flexible printed-wiring board, concentrated photovoltaic power generation module, and light emitting module
WO2020061550A1 (en) 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
EP4063482A4 (en) * 2019-11-21 2022-12-21 Panasonic Intellectual Property Management Co., Ltd. MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM MANUFACTURING METHOD AND PROTEIN MANUFACTURING METHOD
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
WO2022269557A1 (en) * 2021-06-24 2022-12-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
EP4426345A1 (en) 2021-11-05 2024-09-11 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
AU2022379948A1 (en) 2021-11-05 2024-06-20 Sanofi Pasteur Inc. Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
EP4440608A1 (en) 2021-11-30 2024-10-09 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2023242605A1 (en) 2022-06-14 2023-12-21 Támogatott Kutatócsoportok Irodája Extracellular vesicles for use in therapy
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083869A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Product and process for transformation of thraustochytriales microorganisms
US20060275904A1 (en) * 2005-04-28 2006-12-07 Fuji Photo Film Co., Ltd. Method for introducing a gene into Labyrinthulomycota
US20060286650A1 (en) * 2005-04-28 2006-12-21 Fuji Photo Film Co., Ltd. Vector capable for transformation of labyrinthulomycota
US20080022422A1 (en) * 1999-01-14 2008-01-24 Martek Biosciences Corporation Chimeric pufa polyketide synthase systems and uses thereof
WO2009009876A1 (en) * 2007-07-13 2009-01-22 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
CA2180965C (en) * 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
WO1997020854A1 (en) * 1995-12-05 1997-06-12 University Of Massachusetts Recombinant gas vesicles and uses thereof
KR20000075076A (ko) * 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
EP1522590B1 (en) * 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
JP2005538343A (ja) * 2002-04-12 2005-12-15 イラリア・カプア ノイラミニダーゼをコードする精製サブフラグメント、組み換えノイラミニダーゼ、及び動物予防におけるその使用
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
WO2005016961A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
EP2465927B1 (en) * 2004-05-25 2014-12-24 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
WO2006013572A2 (en) * 2004-08-05 2006-02-09 Ben Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP1945250A4 (en) * 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE AGAINST INFLUENZA
WO2007100584A2 (en) * 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
EP3011969A1 (en) * 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009529891A (ja) * 2006-03-15 2009-08-27 マーテック バイオサイエンシーズ コーポレーション 多価不飽和脂肪酸を含む植物種子油
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
JP2009544322A (ja) * 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
MX2010007962A (es) * 2007-11-27 2010-11-10 Medicago Inc Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CA2718529C (en) * 2008-03-19 2014-06-17 Hexion Specialty Chemicals, Inc. Modifier for concrete and cement formulations and methods of preparing the same
ES2752196T3 (es) 2009-03-16 2020-04-03 Dsm Ip Assets Bv Producción de proteínas en microorganismos del filo Labyrinthulomycota
CN103260643A (zh) * 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
EA030095B1 (ru) * 2009-12-28 2018-06-29 ДиЭсЭм АйПи АССЕТС Б.В. Получение белка гемагглютинин-нейраминидазы в микроводорослях

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080022422A1 (en) * 1999-01-14 2008-01-24 Martek Biosciences Corporation Chimeric pufa polyketide synthase systems and uses thereof
WO2002083869A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Product and process for transformation of thraustochytriales microorganisms
US20060275904A1 (en) * 2005-04-28 2006-12-07 Fuji Photo Film Co., Ltd. Method for introducing a gene into Labyrinthulomycota
US20060286650A1 (en) * 2005-04-28 2006-12-21 Fuji Photo Film Co., Ltd. Vector capable for transformation of labyrinthulomycota
WO2009009876A1 (en) * 2007-07-13 2009-01-22 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUHRMANN, M. et al., Methods in Molecular Medicine, 2004, Vol. 94, pages 191-195 *
NWE, N. et al., BMC Microbiology, 2006, Vol. 6, no. 16, pages 1-7 *
SHOJI, Y. et al., 'Plant-expressed HA as a seasonal influenza vaccine candidate', Vaccine, 2008, Vol. 26, No. 23, pages 2930-2934 *
WALKER, T. L. et al., 'Microalgae as bioreactors', Plant Cell Reports, 2005, Vol. 24, No. 11, pages 629-641 *

Also Published As

Publication number Publication date
CA3028175A1 (en) 2011-07-28
JP2023101420A (ja) 2023-07-20
JP2016047055A (ja) 2016-04-07
AU2010343095A1 (en) 2012-08-09
JP6666950B2 (ja) 2020-03-18
JP7585382B2 (ja) 2024-11-18
EP2519635A1 (en) 2012-11-07
EP4130273C0 (en) 2024-06-12
EP3505632A1 (en) 2019-07-03
EP4130273B1 (en) 2024-06-12
US20110189228A1 (en) 2011-08-04
CA2785971C (en) 2019-02-12
AU2017202195B2 (en) 2019-04-18
CN107746869A (zh) 2018-03-02
EP4130273A1 (en) 2023-02-08
AU2019206054B2 (en) 2022-03-10
EA201290567A1 (ru) 2013-02-28
JP2025114812A (ja) 2025-08-05
AU2017202195A1 (en) 2017-04-20
US20200063174A1 (en) 2020-02-27
JP2020096635A (ja) 2020-06-25
CN102822343A (zh) 2012-12-12
JP6339548B2 (ja) 2018-06-06
IN2012DN06277A (forum.php) 2015-09-25
EP2519635B1 (en) 2018-11-21
EP3505632B1 (en) 2022-08-03
EA022841B1 (ru) 2016-03-31
JP2018121660A (ja) 2018-08-09
CN102822343B (zh) 2017-10-20
JP2013515503A (ja) 2013-05-09
CA3153553A1 (en) 2011-07-28
JP5838496B2 (ja) 2016-01-06
AU2022203980B2 (en) 2024-12-12
CA3028175C (en) 2022-05-24
EP2519635A4 (en) 2013-06-26
US20150110826A1 (en) 2015-04-23
WO2011090731A1 (en) 2011-07-28
CA2785971A1 (en) 2011-07-28
AU2022203980A1 (en) 2022-06-30
AU2019206054A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
US20200063174A1 (en) Production of Heterologous Polypeptides in Microalgae, Microalgal Extracellular Bodies, Compositions, and Methods of Making and Uses Thereof
US10829794B2 (en) Protein production in microorganisms of the phylum labyrinthulomycota
JP5838473B2 (ja) 微細藻類におけるヘマグルチニン−ノイラミニダーゼタンパク質の産生方法
CN111315408A (zh) 在嗜热毁丝霉(myceliophthora thermophila)中生产流感疫苗
JP5838496B6 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI VACCINE TECHNOLOGIES, S.A.S.

Free format text: FORMER APPLICANT(S): DSM IP ASSETS B.V.

FGA Letters patent sealed or granted (standard patent)